Chandan Taparia, Derivative & Technical Analyst at Anand Rathi Securities is of the view that Glenmark Pharma may test Rs 740.
Chandan Taparia, Derivative & Technical Analyst at Anand Rathi Securities told CNBC-TV18, " Glenmark Pharma has done well in the entire series, it is up by 7 percent in this series and was up by around 12 percent. So looking at the outperformance, we are still expecting this stock to continue to outperform."
"The stock has seen built up of long positions and showing strong momentum. Trade with a stoploss of Rs 700. On the upside I am looking at a target of Rs 740," he added.
Anda sedang membaca artikel tentang
Glenmark Pharma may test Rs 740: Chandan Taparia
Dengan url
http://sehatgayahidup.blogspot.com/2014/08/glenmark-pharma-may-test-rs-740-chandan.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Glenmark Pharma may test Rs 740: Chandan Taparia
namun jangan lupa untuk meletakkan link
Glenmark Pharma may test Rs 740: Chandan Taparia
sebagai sumbernya
0 komentar:
Posting Komentar